This will be a dose block-randomized, double-blind, active and placebo controlled, single and
multiple dosing, dose-escalation study to evaluate tolerability, safety and
pharmacokinetic/pharmacodynamic characteristics. Adverse events, physical examinations, vital
signs, ECG and laboratory tests will be conducted for safety/tolerability evaluation and
serial blood samples and urine collections for pharmacokinetic and pharmacodynamic
evaluations will be conducted at specified time points.